The group’s principle activity is to develop drugs to treat inherited and acquired energy impairment diseases. The group also develops drugs to treat diseases that impair energy metabolism. The group operates from United States.
Executive Information
Name
Title
Email
Guy Miller
Chmn., CEO
N/A
Patrice Rioux
Chief Medical Officer, VP - Clinical, Regulatory Affairs
